DL-Buthionine-(S,R)-sulfoximine
Based on 37 publication(s) in Google Scholar
DL-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
For research use only. We do not sell to patients.
- Purity : 99.84%
- CAS No.: 5072-26-4
- Formula: C8H18N2O3S
- Molecular Weight:222.31
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DL-Buthionine-(S,R)-sulfoximine
More- Nature. 2026 May;653(8115):933-941. [Abstract]
- Cancer Res. 2025 Aug 21. [Abstract]
- Nat Commun. 2026 Mar 13;17(1):3879. [Abstract]
- Nat Commun. 2024 Aug 30;15(1):7522. [Abstract]
- Redox Biol. 2025 Apr:81:103567. [Abstract]
- Nucleic Acids Res. 2020 Sep 18;48(16):9109-9123. [Abstract]
- Adv Sci (Weinh). 2023 Aug;10(22):e2206798. [Abstract]
- Sci Adv. 2025 Dec 19;11(51):eady2104. [Abstract]
- Sci Adv. 2025 Aug 22;11(34):eadw6926. [Abstract]
- J Control Release. 2025 Sep 30;388(Pt 1):114283. [Abstract]
- Cell Death Dis. 2025 Mar 20;16(1):193. [Abstract]
- Small. 2021 Dec;17(50):e2103984. [Abstract]
- Acta Pharmacol Sin. 2025 Jun 23. [Abstract]
- Environ Int. 2025 Dec 30:207:110032. [Abstract]
- Free Radic Biol Med. 2024 Sep:222:229-243. [Abstract]
- ACS Appl Mater Interfaces. 2025 Mar 21. [Abstract]
- Fundam Res. 2025 Dec 16.
- J Invest Dermatol. 2025 Jul;145(7):1693-1705.e2. [Abstract]
- Eur J Med Chem. 2024 Jan 15:264:115997. [Abstract]
- Ecotoxicol Environ Saf. 2022 Dec 1:247:114263. [Abstract]
- Int Immunopharmacol. 2025 Jun 17:158:114813. [Abstract]
- Algal Res. 2025 Mar.
- Microorganisms. 2026 Apr 9;14(4):851. [Abstract]
- Cell Signal. 2025 Mar:127:111583. [Abstract]
- Med Oncol. 2023 Apr 10;40(5):141. [Abstract]
- Mol Cell Biochem. 2021 Mar;476(3):1631-1642. [Abstract]
- FASEB J. 2024 Jul 31;38(14):e23844. [Abstract]
- Antimicrob Agents Chemother. 2025 Aug 18:e0047125. [Abstract]
- Mol Carcinog. 2025 Sep 25. [Abstract]
- Gene. 2025 Oct 20:970:149785. [Abstract]
- Biochem Biophys Res Commun. 2024 Nov 12:733:150436. [Abstract]
- Biochem Genet. 2024 Sep 24. [Abstract]
- Res Sq. 2026 Jun 15.
- bioRxiv. 2025 March 15.
- Res Sq. 2024 Sep 12:rs.3.rs-5065904. [Abstract]
- Research Square Preprint. 2023 May 24.
- Research Square Print. 2023 Mar 24.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
Description
IC50 & Target
glutamylcysteine synthetase[1]
In Vitro
Buthionine sulfoximine is an analogs of methionine sulfoximine and inhibits gamma-glutamylcysteine synthetase about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 5072-26-4
-
Appearance Solid
-
Molecular Weight 222.31
-
Formula C8H18N2O3S
-
Color White to off-white
-
SMILES
OC(C(N)CCS(CCCC)(=N)=O)=O
-
Synonyms
Buthionine sulfoximine; BSO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (37)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 May;653(8115):933-941. PMID: 41851454 -
Cancer Res
The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma. [Abstract]2025 Aug 21. PMID: 40838989 -
Nat Commun
2026 Mar 13;17(1):3879. PMID: 41820364 -
Nat Commun
SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis. [Abstract]2024 Aug 30;15(1):7522. PMID: 39215042
DL-Buthionine-(S,R)-sulfoximine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 30;15(1):7522. [Abstract]
DL-Buthionine-(S,R)-sulfoximine (BSO; 0-10 μM; 48 h). To determine the effect of ferroptosis, HepG2 and SNU398 cells with or without SLC13A3 knockdown were treated with BSO for 48 h.
-
Redox Biol
Suppression of the LKB1-AMPK-SLC7A11-GSH signaling pathway sensitizes NSCLC to albumin-bound paclitaxel via oxidative stress. [Abstract]2025 Apr:81:103567. PMID: 40023979 -
Nucleic Acids Res
NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest. [Abstract]2020 Sep 18;48(16):9109-9123. PMID: 32729622
DL-Buthionine-(S,R)-sulfoximine purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2020 Sep 18;48(16):9109-9123. [Abstract]
DL-Buthionine-(S,R)-sulfoximine (BSO; 10 μM; 2 h). The glutathione (GSH) levels in A549 cells were measured using the Micro Reduced Glutathione (GSH) Assay Kit 2 h after IR (8 Gy). Cells were pretreated with BSO for 2 h before IR.
-
Adv Sci (Weinh)
Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. [Abstract]2023 Aug;10(22):e2206798. PMID: 37330650
DL-Buthionine-(S,R)-sulfoximine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(22):e2206798. [Abstract]
DL-Buthionine-(S,R)-sulfoximine (BSO; 10 μM; 24 h). Cell death measurements in Huh7 cells treated with donafenib+GSK‐J4 with or without BSO.
-
Sci Adv
Direct recruitment of TONSOKU by the N-terminal tails of histone variants H2A.X and H2A.W coordinates DNA repair. [Abstract]2025 Dec 19;11(51):eady2104. PMID: 41406205 -
Sci Adv
Liver regeneration-associated hepatocellular YAP1 activation prevents colorectal cancer liver metastasis through glutamine competition. [Abstract]2025 Aug 22;11(34):eadw6926. PMID: 40845109 -
J Control Release
Targeting polyamine metabolism induces oxidative/carbonyl stress to reinvigorate antitumor immunity in prostate cancer. [Abstract]2025 Sep 30;388(Pt 1):114283. PMID: 41038348 -
Cell Death Dis
Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis. [Abstract]2025 Mar 20;16(1):193. PMID: 40113760 -
Small
Cell-Derived Biogenetic Gold Nanoparticles for Sensitizing Radiotherapy and Boosting Immune Response against Cancer. [Abstract]2021 Dec;17(50):e2103984. PMID: 34723421
DL-Buthionine-(S,R)-sulfoximine purchased from MedChemExpress. Usage Cited in: Small. 2021 Dec;17(50):e2103984. [Abstract]
DL-Buthionine-(S,R)-sulfoximine (BSO; 500 μM; 12 h). Change of the AuNPs under different pre-treatments.
-
Acta Pharmacol Sin
Ginsenoside (20)S-APPT induces ferroptosis in hepatocellular carcinoma and cholangiocarcinoma by targeting FSP1. [Abstract]2025 Jun 23. PMID: 40550962 -
Environ Int
Integrated network toxicology and molecular docking are used to elucidate the mechanism by which chlorpyrifos induces hepatotoxicity (Cyprinus carpio). [Abstract]2025 Dec 30:207:110032. PMID: 41496238
DL-Buthionine-(S,R)-sulfoximine purchased from MedChemExpress. Usage Cited in: Environ Int. 2025 Dec 30:207:110032. [Abstract]
DL-Buthionine-(S,R)-sulfoximine (BSO; 40 μM; 24 h). The protein expressions of ferroptosis-associated genes.
-
Free Radic Biol Med
Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]2024 Sep:222:229-243. PMID: 38906233 -
ACS Appl Mater Interfaces
Hafnium Metal-Organic Framework-Based Glutamine Metabolism Disruptor For Potentiating Radio-Immunotherapy in MYC-Amplified Hepatocellular Carcinoma. [Abstract]2025 Mar 21. PMID: 40116395 -
-
J Invest Dermatol
Human T Helper 9 Cells Rely on Peroxisome Proliferator-Activated Receptor-γ-Mediated Cystine Uptake to Prevent Lipid Peroxidation and Bioenergetic Failure. [Abstract]2025 Jul;145(7):1693-1705.e2. PMID: 39725162 -
Eur J Med Chem
Design, synthesis, and biological evaluation of 2-amino-6-methyl-phenol derivatives targeting lipid peroxidation with potent anti-ferroptotic activities. [Abstract]2024 Jan 15:264:115997. PMID: 38056303 -
Ecotoxicol Environ Saf
Low-dose arsenite causes overexpression of EGF, TGFα, and HSP90 through Trx1-TXNIP-NLRP3 axis mediated signaling pathways in the human bladder epithelial cells. [Abstract]2022 Dec 1:247:114263. PMID: 36343453 -
Int Immunopharmacol
Exosomes derived from human umbilical cord mesenchymal stem cells attenuate senescence of peritoneal mesothelial cells by inhibiting oxidative stress. [Abstract]2025 Jun 17:158:114813. PMID: 40354711 -
-
Microorganisms
Biochanin A Exerts Broad-Spectrum Antiviral Activity Against Coronaviruses via Activating the AMPK/Nrf2/GSH Pathway. [Abstract]2026 Apr 9;14(4):851. PMID: 42075248 -
Cell Signal
HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism. [Abstract]2025 Mar:127:111583. PMID: 39756501 -
Med Oncol
2023 Apr 10;40(5):141. PMID: 37036615 -
Mol Cell Biochem
Moderate oxidative stress promotes epithelial-mesenchymal transition in the lens epithelial cells via the TGF-β/Smad and Wnt/β-catenin pathways. [Abstract]2021 Mar;476(3):1631-1642. PMID: 33417163 -
FASEB J
Desaminotyrosine is a redox-active microbial metabolite that bolsters macrophage antimicrobial functions while attenuating IL-6 production. [Abstract]2024 Jul 31;38(14):e23844. PMID: 39046365 -
Antimicrob Agents Chemother
Synergistic activity of RSL3 and Pyrimethamine to inhibit the proliferation of Plasmodium falciparum. [Abstract]2025 Aug 18:e0047125. PMID: 40823867 -
Mol Carcinog
Inhibiting Cyclin-Dependent Kinase 13-Mediated Nuclear Ubiquitous Casein Kinase and Cyclin-Dependent Kinase Substrate 1 Phosphorylation Facilitates Oxidative Stress-Induced Apoptosis in Melanoma. [Abstract]2025 Sep 25. PMID: 40994213 -
Gene
Menaquinone-4 ameliorates abdominal aortic aneurysm by suppressing ferroptosis through NRF2/GCLM axis. [Abstract]2025 Oct 20:970:149785. PMID: 40992546 -
Biochem Biophys Res Commun
2024 Nov 12:733:150436. PMID: 39053102 -
Biochem Genet
Study on the Mechanism of FOXA2 Activation on Glutathione Metabolic Reprogramming Mediated by ETV4 Transcription to Facilitate Colorectal Cancer Malignant Progression. [Abstract]2024 Sep 24. PMID: 39316306 -
-
-
Res Sq
BMP receptor 2 inhibition regulates mitochondrial bioenergetics to induce synergistic cell death with BCL-2 inhibitors in leukemia and NSLC cells. [Abstract]2024 Sep 12:rs.3.rs-5065904. PMID: 39315260 -
-
Solvent & Solubility
In Vitro:
H2O : ≥ 50 mg/mL (224.91 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (449.82 mM); Clear solution; Need ultrasonic
Protocol
Animal Administration[2]
Mice[2]
D,L-Buthionine-(S,R)-sulfoximine is dissolved in sterile 0.9% saline, filtered through a 0.2-p.m polysulfone membrane filter, and administered by 48-h continuous iv. infusion at a dose of 300 mg/kg/day and 600 mg/kg/day starting at 24 h before doxorubicin administration. In vivo GSH levels after treatment with D,L-Buthionine-(S,R)-sulfoximine at a dose of 300 mg/kg and 600 mg/kg for 24 h as an iv. continuous infusion in munine plasma and in tumor tissue of HT1080 and HT1080/DR4 xenografts is measured[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Griffith OW, et al. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979 Aug 25;254(16):7558-60. [Content Brief]
[2]. Vanhoefer U, et al. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996 Dec;2(12):1961-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.4982 mL | 22.4911 mL | 44.9822 mL | 112.4556 mL |
| 5 mM | 0.8996 mL | 4.4982 mL | 8.9964 mL | 22.4911 mL | |
| 10 mM | 0.4498 mL | 2.2491 mL | 4.4982 mL | 11.2456 mL | |
| 15 mM | 0.2999 mL | 1.4994 mL | 2.9988 mL | 7.4970 mL | |
| 20 mM | 0.2249 mL | 1.1246 mL | 2.2491 mL | 5.6228 mL | |
| 25 mM | 0.1799 mL | 0.8996 mL | 1.7993 mL | 4.4982 mL | |
| 30 mM | 0.1499 mL | 0.7497 mL | 1.4994 mL | 3.7485 mL | |
| 40 mM | 0.1125 mL | 0.5623 mL | 1.1246 mL | 2.8114 mL | |
| 50 mM | 0.0900 mL | 0.4498 mL | 0.8996 mL | 2.2491 mL | |
| 60 mM | 0.0750 mL | 0.3749 mL | 0.7497 mL | 1.8743 mL | |
| 80 mM | 0.0562 mL | 0.2811 mL | 0.5623 mL | 1.4057 mL | |
| 100 mM | 0.0450 mL | 0.2249 mL | 0.4498 mL | 1.1246 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
DL-Buthionine-(S,R)-sulfoximine Related Classifications
HY-106376 Related Classifications
Powered by Bioz